Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) had its target price increased by Morgan Stanley from $205.00 to $210.00 in a research report released on Tuesday, Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company’s stock. A number of other research analysts have also issued reports on the company. JPMorgan Chase […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 4,930,000 shares, a decline of 8.5% from the February 28th total of 5,390,000 shares. Based on an average daily volume of 781,100 shares, the days-to-cover ratio is currently 6.3 days. […]
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) have been given an average rating of “Moderate Buy” by the twenty-two research firms that are presently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average […]
Verition Fund Management LLC bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 4,827 shares of the biopharmaceutical company’s stock, valued at approximately $966,000. A number of other hedge funds have also […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) had its target price boosted by research analysts at HC Wainwright from $350.00 to $400.00 in a report issued on Tuesday, The Fly reports. HC Wainwright’s target price suggests a potential upside of 154.08% from the stock’s current price. Several other equities analysts also recently weighed in on ALNY. […]